Evidence map›Paper›PMID 41323652›Full record

ArticleFrontiers in aging neuroscience2025

Integrated analysis of N-glycosylation and Alzheimer's disease: identifying key biomarkers and mechanisms.

Hao Zhang, WenJun Chen, ShuYou Yuan, Bo Cai, ShaoXiang Ding, HongXia Bao, JunKai Sun, Wei Lu, HaoGang Zhu

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hao ZhangGeriatrics Center, Wuxi Second Geriatric Hospital, Wuxi, China.
WenJun ChenDepartment of Neurology, Wuxi Second Geriatric Hospital, Wuxi, China.
ShuYou YuanDepartment of Laboratory, Wuxi Second Geriatric Hospital, Wuxi, China.
Bo CaiDepartment of Pathology, Wuxi Second Geriatric Hospital, Wuxi, China.
ShaoXiang DingGeriatrics Center, Wuxi Second Geriatric Hospital, Wuxi, China.
HongXia BaoGeriatrics Center, Wuxi Second Geriatric Hospital, Wuxi, China.
JunKai SunDepartment of Interventional Radiology, Wuxi No. 5 People's Hospital, Wuxi, China.
Wei LuGeriatrics Center, Wuxi Second Geriatric Hospital, Wuxi, China.
HaoGang ZhuGeriatrics Center, Wuxi Second Geriatric Hospital, Wuxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's disease (AD) is the most prevalent cause of dementia in the elderly, imposing a significant societal burden. Current therapeutic approaches primarily address symptoms, underscoring the critical need to elucidate its pathogenesis and identify robust early biomarkers. N-glycosylation, a critical post-translational modification, is dysregulated in neurodegenerative disorders, yet its role in AD and diagnostic potential remain underexplored. Objective: This investigation aimed to characterize the interplay between N-glycosylation and AD through multi-dimensional bioinformatics analysis, identify core differentially expressed genes (DEGs) associated with this crosstalk, and evaluate their diagnostic efficacy in early AD detection. Methods: A bibliometric analysis of Web of Science literature spanning 2001-2025 was performed using VOSviewer, CiteSpace, and R. Transcriptomic data were analyzed with LIMMA to identify DEGs. Feature prioritization and molecular interaction decoding were achieved through Lasso, Random Forest, XGBoost, and SHAP analysis. Results: Bibliometric analysis highlighted a shift toward granular molecular mechanisms, with "bisecting GlcNAc" and "GNT-III (MGAT3)" emerging as key research topics. Differential expression profiling identified 6,845 DEGs, including TMEM59, MLEC, and MAX. Machine learning algorithms consistently prioritized these three genes as core N-glycosylation-related biomarkers, alongside APP as a key associated molecule. Among transcription factors, MAX was identified as a central regulator, with a subset of 8 factors (including MAX and BRD9) pinpointed as critical modulators of N-glycosylation and glial activation in AD. Diagnostic models demonstrated strong performance: logistic regression achieved an AUC of 0.947 with MAX, APP, and MLEC; Random Forest and XGBoost attained perfect AUC = 1.0 in primary analyses; and a clinical nomogram integrating core genes yielded an AUC of 0.899. SHAP analysis confirmed MAX, APP, MLEC, and TMEM59 as top predictors, revealing significant positive interactions between MLEC and TMEM59 ( Conclusion: MAX, MLEC, and TMEM59 represent key N-glycosylation-linked diagnostic biomarkers for AD. This integrative framework provides novel insights into AD pathogenesis and lays the foundation for personalized diagnostic tools and therapies, warranting experimental validation.

Indexed as

Alzheimer’s diseasediagnostic biomarkersmachine learningN-glycosylationtranscription factors

Identifiers

PMID41323652
PMCPMC12657396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.